Paul E Sax Selected Research

lamivudine drug combination abacavir

1/2019	Race/Ethnicity and Protease Inhibitor Use Influence Plasma Tenofovir Exposure in Adults Living with HIV-1 in AIDS Clinical Trials Group Study A5202.
9/2014	Changes in proteinuria and albuminuria with initiation of antiretroviral therapy: data from a randomized trial comparing tenofovir disoproxil fumarate/emtricitabine versus abacavir/lamivudine.
3/2014	Cystatin C-based renal function changes after antiretroviral initiation: a substudy of a randomized trial.
2/2013	Changes in fat mitochondrial DNA and function in subjects randomized to abacavir-lamivudine or tenofovir DF-emtricitabine with atazanavir-ritonavir or efavirenz: AIDS Clinical Trials Group study A5224s, substudy of A5202.
7/2012	Inflammation markers after randomization to abacavir/lamivudine or tenofovir/emtricitabine with efavirenz or atazanavir/ritonavir.
10/2011	Abacavir/lamivudine versus tenofovir DF/emtricitabine as part of combination regimens for initial treatment of HIV: final results.
6/2011	Bone mineral density and fractures in antiretroviral-naive persons randomized to receive abacavir-lamivudine or tenofovir disoproxil fumarate-emtricitabine along with efavirenz or atazanavir-ritonavir: Aids Clinical Trials Group A5224s, a substudy of ACTG A5202.
12/2009	Abacavir-lamivudine versus tenofovir-emtricitabine for initial HIV-1 therapy.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Paul E Sax Research Topics

Disease

27	Acquired Immunodeficiency Syndrome (AIDS) 11/2020 - 07/2004
26	Infections 01/2021 - 04/2006
18	HIV Infections (HIV Infection) 10/2020 - 09/2002
7	Coinfection 01/2020 - 06/2003
6	Viremia 11/2020 - 12/2003
6	Insulin Resistance 01/2019 - 04/2003
5	Inflammation (Inflammations) 10/2020 - 07/2012
5	Nausea 10/2020 - 06/2012
4	Weight Gain 10/2021 - 01/2020
4	Headache (Headaches) 01/2020 - 11/2017
4	Pneumocystis Pneumonia (Pneumocystis carinii Pneumonia) 12/2019 - 07/2011
4	Proteinuria 01/2019 - 09/2014
4	Hepatitis B 01/2018 - 12/2003
3	Dizziness (Lightheadedness) 01/2019 - 06/2012
3	Hepatitis C 11/2017 - 12/2012
3	Opportunistic Infections (Opportunistic Infection) 07/2011 - 09/2010
2	COVID-19 01/2022 - 01/2022
2	Exanthema (Rash) 01/2021 - 06/2012
2	Heart Failure 01/2020 - 01/2019
2	Pneumonia (Pneumonitis) 12/2019 - 06/2008
2	Chronic Hepatitis B 01/2019 - 11/2017
2	Lymphoma (Lymphomas) 01/2019 - 06/2004
2	Cardiovascular Diseases (Cardiovascular Disease) 01/2017 - 07/2008
2	Fibrosis (Cirrhosis) 08/2015 - 08/2006
1	Perinatal Death 01/2021
1	Bacterial Pneumonia 10/2020
1	Respiratory Tract Infections (Respiratory Tract Infection) 01/2020
1	Substance-Related Disorders (Drug Abuse) 01/2020
1	Malaria 04/2019
1	Adenocarcinoma 01/2019
1	Sleep Wake Disorders 01/2019
1	Heart Arrest (Cardiac Arrest) 01/2019

Drug/Important Bio-Agent (IBA)

23	Emtricitabine (Emtriva)FDA Link 01/2021 - 03/2009
23	Tenofovir (Viread)FDA Link 01/2021 - 02/2007
18	efavirenz (Sustiva)FDA Link 01/2021 - 12/2009
12	dolutegravirIBA 01/2021 - 03/2016
12	RNA (Ribonucleic Acid)IBA 12/2020 - 12/2003
10	Ritonavir (Norvir)FDA Link 01/2020 - 12/2009
10	Atazanavir Sulfate (Reyataz)FDA Link 01/2019 - 12/2009
9	tenofovir alafenamideIBA 01/2021 - 09/2014
8	Protease Inhibitors (Protease Inhibitor)IBA 12/2020 - 12/2009
8	Pharmaceutical PreparationsIBA 12/2020 - 07/2009
8	lamivudine drug combination abacavir FDA Link 01/2019 - 12/2009
7	Lamivudine (Epivir)FDA Link 01/2021 - 03/2016
7	Biomarkers (Surrogate Marker)IBA 01/2019 - 09/2004
6	RacivirIBA 01/2021 - 10/2011
5	abacavir (Ziagen)FDA Link 10/2021 - 10/2008
5	Reverse Transcriptase InhibitorsIBA 12/2020 - 12/2009
5	bictegravirIBA 12/2020 - 01/2017
5	elvitegravirIBA 12/2020 - 06/2012
5	CobicistatIBA 12/2020 - 06/2012
5	Antiviral Agents (Antivirals)IBA 10/2020 - 07/2016
4	doravirineIBA 01/2021 - 01/2018
4	NucleosidesIBA 12/2020 - 08/2006
4	CreatinineIBA 01/2019 - 03/2014
4	TabletsIBA 01/2019 - 06/2012
4	Anti-Retroviral Agents (Antiretroviral Agents)IBA 07/2009 - 05/2004
3	LipidsIBA 01/2021 - 05/2004
3	IntegrasesIBA 12/2020 - 01/2018
3	Darunavir (Prezista)FDA Link 01/2020 - 01/2013
3	CholesterolIBA 01/2020 - 11/2002
3	Glucose (Dextrose)FDA LinkGeneric 06/2014 - 05/2004
3	beta-GlucansIBA 11/2013 - 06/2008
3	DNA (Deoxyribonucleic Acid)IBA 05/2010 - 06/2004
3	VaccinesIBA 05/2010 - 05/2005
2	NucleotidesIBA 12/2020 - 09/2014
2	Triglycerides (Triacylglycerol)IBA 01/2020 - 09/2004
2	HLA-B Antigens (HLA-B)IBA 01/2020 - 10/2008
2	polyglucosanIBA 12/2019 - 07/2011
2	Mitochondrial DNA (mtDNA)IBA 01/2019 - 02/2013
2	AdiponectinIBA 01/2019 - 05/2004
2	Raltegravir Potassium FDA Link 01/2018 - 11/2017
2	Peptide Hydrolases (Proteases)FDA Link 01/2018 - 12/2012
2	RNA-Directed DNA Polymerase (Reverse Transcriptase)IBA 01/2018 - 12/2012
2	Cystatin CIBA 06/2015 - 03/2014
2	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 02/2014 - 06/2007
2	Amino Acids FDA Link 12/2012 - 12/2010
1	Complement System Proteins (Complement)IBA 01/2022
1	Adrenal Cortex Hormones (Corticosteroids)IBA 01/2022
1	remdesivirIBA 01/2022
1	Oxygen (Dioxygen)IBA 01/2022
1	FumaratesIBA 01/2021
1	Zidovudine (Retrovir)FDA LinkGeneric 12/2020
1	Rilpivirine (TMC-278)IBA 12/2020
1	omadacyclineIBA 10/2020
1	ibalizumabIBA 01/2020
1	oxidized low density lipoproteinIBA 01/2020
1	Ribavirin (Virazole)FDA LinkGeneric 01/2020
1	Anti-Bacterial Agents (Antibiotics)IBA 12/2019
1	Antimalarials (Antimalarial Agents)IBA 04/2019
1	Testosterone (Sustanon)FDA Link 01/2019
1	P-30 composite resin (P 30)IBA 01/2019
1	beta 2-Microglobulin (beta 2 Microglobulin)IBA 01/2019

Therapy/Procedure

26	Therapeutics 12/2020 - 09/2002
11	Art Therapy 10/2021 - 09/2002
6	Highly Active Antiretroviral Therapy (HAART) 09/2010 - 04/2003
1	Noninvasive Ventilation 01/2022
1	Extracorporeal Membrane Oxygenation 01/2022
1	Artificial Respiration (Mechanical Ventilation) 01/2022
1	Chemoprevention 04/2019